Overexpression of amyloid precursor protein is associated with degeneration, decreased viability, and increased damage caused by neurotoxins (prostaglandins A1 and E2, hydrogen peroxide, and nitric oxide) in differentiated neuroblastoma cells

Journal of Neuroscience Research

Volumn 74, Issue 1, 2003, Pages 148-159

  Hanson, Amy J ^a   Prasad, Judith E ^a   Nahreini, Piruz ^a   Andreatta, Cynthia ^a   Kumar, Bipin ^a   Yan, Xiang Dong ^a   Prasad, Kedar N ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

amyloid; Alzheimer's disease; Amyloid precursor protein; Differentiated neuroblastoma cells; Hydrogen peroxide; Nitric oxide donor; Prostaglandin

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CYCLIC AMP; HYDROGEN PEROXIDE; MESSENGER RNA; NEUROTOXIN; NITRIC OXIDE; PROSTAGLANDIN A1; PROSTAGLANDIN E2;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENZYME INHIBITION; HUMAN; INFLAMMATION; MOUSE; NERVE CELL DIFFERENTIATION; NERVE CELL LESION; NERVE DEGENERATION; NEUROBLASTOMA CELL; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION REGULATION; HUMANS; HYDROGEN PEROXIDE; MICE; NERVE DEGENERATION; NEUROBLASTOMA; NEUROTOXINS; NITRIC OXIDE; PROSTAGLANDINS A; TUMOR CELLS, CULTURED;

EID: 0141646264     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10726     Document Type: Article

References (61)

1. Aliev G, Smith MA, Seyidov D, Neal ML, Lamb BT, Nunomura A, Gasimov EK, Vinters HV, Perry G, LaManna JC, Friedland RP. 2002. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol 12:21-35.
2. Behl C, Davis JB, Lesley R, Schubert D. 1994. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77:817-827.
3. Bourbonniere M, Shekarabi M, Nalbantoglu J. 1997. Enhanced expression of amyloid precursor protein in response to dibutyryl cyclic AMP is not mediated by the transcription factor AP-2. J Neurochem 68:909-916.
4. Butterfield DA, Kanski J. 2002. Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide 1-42. Peptides 23:1299-1309.
5. Butterfield DA, Hensley K, Harris M, Mattson M, Carney J. 1994. Beta-amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochem Biophys Res Commun 200:710-715.
6. Butterfield DA, Castegna A, Drake J, Scapagnini G, Calabrese V. 2002. Vitamin E and neurodegenerative disorders associated with oxidative stress. Nutr Neurosci 5:229-239.
7. Checler F, da Costa CA, Ancolio K, Chevallier N, Lopez-Perez E, Marambaud P. 2000. Role of the proteasome in Alzheimer's disease. Biochim Biophys Acta 1502:133-138.
8. Chen L, Richardson JS, Caldwell JE, Ang LC. 1994. Regional brain activity of free radical defense enzymes in autopsy samples from patients with Alzheimer's disease and from nondemented controls. Int J Neurosci 75:83-90.
9. Dewji NN, Singer SJ. 1996. Genetic clues to Alzheimer's disease. Science 271:159-160.
10. Dick LR, Cruikshank AA, Destree AT, Grenier L, McCormack TA, Melandri FD, Nunes SL, Palombella VJ, Parent LA, Plamondon L, Stein RL. 1997. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J Biol Chem 272:182-188.
11. Efthimiopoulos S, Punj S, Manolopoulos V, Pangalos M, Wang GP, Refolo LM, Robakis NK. 1996. Intracellular cyclic AMP inhibits constitutive and phorbol ester-stimulated secretory cleavage of amyloid precursor protein. J Neurochem 67:872-875.
12. Frohman EM, Frohman TC, Gupta S, de Fougerolles A, van den Noort S. 1991. Expression of intercellular adhesion molecule 1 (ICAM-1) in Alzheimer's disease. J Neurol Sci 106:105-111.
13. Gegelashvili G, Bock E, Schousboe A, Linnemann D. 1996. Two types of amyloid precursor protein (APP) mRNA in rat glioma cell lines: upregulation via a cyclic AMP-dependent pathway. Brain Res Mol Brain Res 37:151-156.
14. Gotz ME, Kunig G, Riederer P, Youdim MB. 1994. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63:37-122.
15. Gregori L, Hainfeld JF, Simon MN, Goldgaber D. 1997. Binding of amyloid beta protein to the 20 S proteasome. J Biol Chem 272:58-62.
16. Harman D. 1995. Free radical theory of aging: Alzheimer's disease pathogenesis. Age 18:97-119.
17. Hoozemans JJ, Veerhuis R, Rozemuller AJ, Eikelenboom P. 2002. The pathological cascade of Alzheimer's disease: the role of inflammation and its therapeutic implications. Drugs Today 38:429-443.
18. Hovland AR, Nahreini P, Andreatta CP, Edwards-Prasad J, Prasad KN. 2001. Identifying genes involved in regulating differentiation of neuroblastoma cells. J Neurosci Res 64:302-310.
19. Koppal T, Drake J, Yatin S. 1998. Peroxynitrite-mediated damage to brain membrane proteins and lipids: another oxidative pathway for membrane alterations in Alzheimer's disease (AD). Soc Neurosci Abstr 24:1217a.
20. Kumar A, La Rosa FG, Hovland AR, Cole WC, Edwards-Prasad J, Prasad J, Prasad KN. 1999. Adenosine 3′,5′-cyclic monophosphate increases processing of amyloid precursor protein (APP) to beta-amyloid in neuroblastoma cells without changing APP levels or expression of APP mRNA. Neurochem Res 24:1209-1215.
21. Kumar B, Andreatta C, Koustas WT, Cole WC, Edwards-Prasad J, Prasad KN. 2002. Mevastatin induces degeneration and decreases viability of cAMP-induced differentiated neuroblastoma cells in culture by inhibiting proteasome activity, and mevalonic acid lactone prevents these effects. J Neurosci Res 68:627-635.
22. Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini E, Schneider LS. 2003. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets 4:97-112.
23. Lee RK, Araki W, Wurtman RJ. 1997. Stimulation of amyloid precursor protein synthesis by adrenergic receptors coupled to cAMP formation. Proc Natl Acad Sci USA 94:5422-5426.
24. Lovell MA, Xie C, Markesbery WR. 1998. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology 51:1562-1566.
25. Lue L-F, Rogers J. 1992. Full complement activation fails in diffuse plaques of the Alzheimer's disease cerebellum. Dementia 3:308.
26. Mattson MP. 2002. Oxidative stress, perturbed calcium homeostasis, and immune dysfunction in Alzheimer's disease. J Neurovirol 8:539-550.
27. Miller AD, Rosman GJ. 1989. Improved retroviral vectors for gene transfer and expression. Biotechniques 7:980-982, 984-986, 989-990.
28. 2 levels in patients with probable AD. Neurology 53:1495-1498.
29. Morishima-Kawashima M, Ihara Y. 2002. Alzheimer's disease: beta-Amyloid protein and tau. J Neurosci Res 70:392-401.
30. Morrow JD, Roberts LJ. 1997. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 36:1-21.
31. Nahreini P, Andreatta C, Prasad KN. 2001a. Proteasome activity is critical for the cAMP-induced differentiation of neuroblastoma cells. Cell Mol Neurobiol 21:509-521.
32. Nahreini P, Hovland AR, Kumar B, Andreatta C, Edwards-Prasad J, Prasad KN. 2001b. Effects of altered cyclophilin A expression on growth and differentiation of human and mouse neuronal cells. Cell Mol Neurobiol 21:65-79.
33. Nahreini P, Andreatta C, Kumar B, Hanson A, Edwards-Prasad J, Freed CR, Prasad KN. 2003a. Distinct patterns of gene expression induced by viral oncogenes in human embryonic brain cells. Cell Mol Neurobiol 23:27-42.
34. Nahreini P, Hanson AJ, Prasad KN. 2003b. Enrichment of cells exhibiting tetracycline regulated gene expression. Biotechniques 34:958-968.
35. Neve RL, McPhie DL, Chen Y. 2001. Alzheimer's disease: dysfunction of a signalling pathway mediated by the amyloid precursor protein? Biochem Soc Symp. p 37-50.
36. Olanow CW, Arendash GW. 1994. Metals and free radicals in neurodegeneration. Curr Opin Neurol 7:548-558.
37. Pear WS, Nolan GP, Scott ML, Baltimore D. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90:8392-8396.
38. Prasad KN. 1991. Differentiation of neuroblastoma cells: a useful model for neurobiology and cancer. Biol Rev Camb Philos Soc 66:431-451.
39. Prasad KN, Mandal B, Waymire JC, Lees GJ, Vernadakis A, Weiner N. 1973. Basal level of neurotransmitter synthesizing enzymes and effect of cyclic AMP agents on the morphological differentiation of isolated neuroblastoma clones. Nat New Biol 241:117-119.
40. Prasad KN, La Rosa FG, Prasad JE. 1998a. Prostaglandins act as neurotoxin for differentiated neuroblastoma cells in culture and increase levels of ubiquitin and beta-amyloid. In Vitro Cell Dev Biol Anim 34:265-274.
41. Prasad KN, Hovland AR, La Rosa FG, Hovland PG. 1998b. Prostaglandins as putative neurotoxins in Alzheimer's disease. Proc Soc Exp Biol Med 219:120-125.
42. Rao AV, Balachandran B. 2002. Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr Neurosci 5:291-309.
43. Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. 1999. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 96:7797-7802.
44. Reich EE, Zackert WE, Brame CJ, Chen Y, Roberts LJ 2nd, Hachey DL, Montine TJ, Morrow JD. 2000. Formation of novel D-ring and E-ring isoprostane-like compounds (D4/E4-neuroprostanes) in vivo from docosahexaenoic acid. Biochemistry 39:2376-2383.
45. Richardson JS, Subbarao KV, Ang LC. 1992. On the possible role of iron-induced free radical peroxidation in neural degeneration in Alzheimer's disease. Ann N Y Acad Sci 648:326-327.
46. Roberts LJ 2nd, Morrow JD. 2001. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman JS, Limbird LE, Gilman AG, editors. Goodman & Gilman's the pharmacological basis of therapeutics, 10th ed. New York: McGraw-Hill. p 687-731.
47. Roberts LJ 2nd, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, Dettbarn WD, Morrow JD. 1998. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 273:13605-13612.
48. Rockwell P, Yuan H, Magnusson R, Figueiredo-Pereira ME. 2000. Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2). Arch Biochem Biophys 374:325-333.
49. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, et al. 1992. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 89:10016-10020.
50. Rogers J, Lue L-F, Brachova L, Webster S, Shultz J. 1995. Inflammation as a response and as a cause of Alzheimer's pathophysiology. Dementia 9:133-138.
51. Rozemuller JM, Eikelenboom P, Pals ST, Stam FC. 1989. Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci Lett 101:288-292.
52. Sambamurti K, Shioi J, Anderson JP, Pappolla MA, Robakis NK. 1992. Evidence for intracellular cleavage of the Alzheimer's amyloid precursor in PC12 cells. J Neurosci Res 33:319-329.
53. Schipper HM, Cisse S, Stopa EG. 1995. Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Ann Neurol 37:758-768.
54. Schubert D, Behl C, Lesley R, Brack A, Dargusch R, Sagara Y, Kimura H. 1995. Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci USA 92:1989-1993.
55. Selkoe DJ. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766.
56. Shalit F, Sredni B, Stern L, Kott E, Huberman M. 1994. Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer's patients. Neurosci Lett 174:130-132.
57. Sharif SF, Hariri RJ, Chang VA, Barie PS, Wang RS, Ghajar JB. 1993. Human astrocyte production of tumour necrosis factor-alpha, interleukin-1 beta, and interleukin-6 following exposure to lipopolysaccharide endotoxin. Neurol Res 15:109-112.
58. Smith MA, Kutty RK, Richey PL, Yan SD, Stern D, Chader GJ, Wiggert B, Petersen RB, Perry G. 1994. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 145:42-47.
59. Verbeek MM, Otte-Holler I, Westphal JR, Wesseling P, Ruiter DJ, de Waal RM. 1994. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. Am J Pathol 144:104-116.
60. Yan SD, Roher A, Chaney M, Zlokovic B, Schmidt AM, Stern D. 2000. Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide. Biochim Biophys Acta 1502:145-157.
61. Yankner BA, Mesulam MM. 1991. Seminars in medicine of the Beth Israel Hospital, Boston. Beta-amyloid and the pathogenesis of Alzheimer's disease. N Engl J Med 325:1849-1857.